BioCentury
ARTICLE | Clinical News

Integrilin eptifibatide: Phase II data; marketed to treat unstable angina and non-Q-wave myocardial infarction and as an adjunct to coronary angioplasty

November 15, 1999 8:00 AM UTC

In CORR and partner Schering-Plough Corp.'s 340-patient Phase II INTRO-AMI study, the combination of Integrilin and half the normal dose of Genentech Inc.'s Activase alteplase tPA restored normal blood flow through clogged arteries in 78 percent of patients. CORR said that in previous studies of full-dose alteplase monotherapy, 54 percent of heart attack patients had restored blood flow.

Data were presented at the American Heart Association meeting in Atlanta. The ongoing second stage of INTRO-AMI is comparing coronary blood flow restoration with two Integrilin doses combined with half-dose alteplase to full-dose alteplase alone. ...